ABC | Volume 114, Nº3, March 2020

Statement Brazilian Position Statement on Resistant Hypertension – 2020 Arq Bras Cardiol. 2020; 114(3):576-596 144. Santos LP, Moraes RS, Vieira PJ, Ash GI, Waclawovsky G, Pescatello LS, et al. Effects of aerobic exercise intensity on ambulatory blood pressure and vascular responses in resistant hypertension: a crossover trial. J Hypertens. 2016;34(7):1317-24. 145. Kruk PJ, Nowicki M. Effect of the physical activity program on the treatment of resistant hypertension in primary care. Prim Health Care Res Dev. 2018; 22:1-9. 146. Cruz LG, Bocchi EA, Grassi G, Guimaraes GV. Neurohumoral and Endothelial Responses to Heated Water-Based Exercise in Resistant Hypertensive Patients. Circ J. 2017;81(3):339-45. 147. Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension. 2011;58(5):950-8. 148. Narayan P, Doumas M, Kumar A, Faselis CJ, Myers JN, Pittaras A, et al. Impact of Cardiorespiratory Fitness on Mortality in Black Male Veterans With Resistant Systemic Hypertension. Am J Cardiol. 2017;120(9):1568-71. 149. Povoa R, Barroso WS, Brandao AA, Jardim PC, Barroso O, Passarelli O, Jr., et al. I brazilian position paper on antihypertensive drug combination. Arq Bras Cardiol. 2014;102(3):203-10. 150. Whelton PK, Carey RM, AronowWS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115. 151. Salles GF, Cardoso CR, Fonseca LL, Fiszman R, Muxfeldt ES. Prognostic significance of baseline heart rate and its interaction with beta- blocker use in resistant hypertension: a cohort study. Am J Hypertens. 2013;26(2):218-26. 152. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-68. 153. Liu G, Zheng XX, Xu YL, Lu J, Hui RT, Huang XH. Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis. J Hum Hypertens. 2015;29(3):159-66. 154. Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, et al. The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies. Am J Hypertens. 2015;28(11):1376-85. 155. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6(6):464-75. 156. van Kleef MEAM, Bates MC, Spiering W. Endovascular Baroreflex Amplification for Resistant Hypertension. Curr Hypertens Report. 2018;20(5):46. 157. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765-73. 158. Heusser K, Tank J, Brinkmann J, Menne J, Kaufeld J, Linnenweber- Held S, et al. Acute Response to Unilateral Unipolar Electrical Carotid Sinus Stimulation in Patients with Resistant Arterial Hypertension. Hypertension. 2016;67(3):585-91. 159. Wallbach M, Lehnig LY, Schroer C, Luders S, Bohning E, Muller GA, et al. Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension. Hypertension. 2016;67(4):701-9. 160. Schmieder RE, Mahfoud F, Azizi M, Pathak A, Dimitriadis K, Kroon AA, et al. European Society of Hypertension position paper on renal denervation. J Hypertens. 2018;391(10137):2335-45. 161. OparilS,SchmiederRE.Newapproaches inthetreatmentofhypertension. Circ Res. 2015;116(6):1074-95. 162. Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65(13):1314-21. 163. Pappaccogli M, Covella M, Berra E, Fulcheri C, Di Monaco S, Perlo E, et al. Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11Controlled Studies. High Blood Press Cardiovasc Prev. 2018;25(2):167-76. 164. Morganti A, Mancia G. Resistant hypertension: Renal denervation or intensified medical treatment? Eur J Intern Med. 2018;50:6-11. 165. Lozano L, Tovar JL, Sampol G, Romero O, Jurado MJ, Segarra A, et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. J Hypertens. 2010 ;28(10):2161-8. 166. Pedrosa RP, Drager LF, de Paula LKG, Amaro ACS, Bortolotto LA, Lorenzi-Filho G. Effects of OSA treatment on BP in patients with resistant hypertension: a randomized trial. Chest. 2013;144(5):1487-94. 167. Martinez-Garcia MA, Capote F, Campos-Rodriguez F, Lloberes P, Diaz de Atauri MJ, Somoza M, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA. 2013;310(22):2407-15. 168. deOliveira AC, Martinez D, Massierer D, Gus M, Goncalves SC, Ghizzoni F, et al. The antihypertensive effect of positive airway pressure on resistant hypertension of patients with obstructive sleep apnea: a randomized, double-blind,clinicaltrial.Am JRespirCritCareMed.2014;190(3):345-7. 169. MuxfeldtES,MargalloV,CostaLM,GuimaraesG,CavalcanteAH,Azevedo JC, et al. Effects of continuous positive airway pressure treatment on clinic and ambulatory blood pressures in patients with obstructive sleep apnea and resistant hypertension: a randomized controlled trial. Hypertension. 2015;65(4):736-42. 170. Litvin AY, Sukmarova ZN, Elfimova EM, Aksenova AV, Galitsin PV, Rogoza AN, et al. Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension. Vasc Health Risk Manag. 2013;9:229-35. 171. Joyeux-FaureM, Baguet JP, Barone-RochetteG, Faure P, Sosner P, Mounier- Vehier C, et al. Continuous Positive Airway Pressure Reduces Night-Time Blood Pressure and Heart Rate in Patients With Obstructive Sleep Apnea andResistantHypertension:TheRHOOSASRandomizedControlledTrial. Front Neurol. 2018;9:318. 172. Sanchez-de-la-Torre M, Khalyfa A, Sanchez-de-la-Torre A, Martinez- Alonso M, Martinez-Garcia MA, Barcelo A, et al. Precision Medicine in PatientsWith Resistant Hypertension andObstructive SleepApnea: Blood Pressure Response to Continuous Positive Airway Pressure Treatment. J Am Coll Cardiol. 2015;66(9):1023-32. 173. Bertog SC, Sobotka NA, Sobotka PA, Lobo MD, Sievert K, Vaskelyte L, et al. Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension. Curr Hypertens Rep. 2018;20(3):18. 174. Lobo MD, Sobotka PA, Stanton A, Cockcroft JR, Sulke N, Dolan E, et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet. 2015;385(9978):1634-41. 595